Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 241

Results For "FY"

2435 News Found

Indian vaccine players to garner Rs. 70,599 Cr in 2021
News | April 30, 2021

Indian vaccine players to garner Rs. 70,599 Cr in 2021

Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong


Glenmark’s Ryaltris nasal spray approved in Europe
News | April 27, 2021

Glenmark’s Ryaltris nasal spray approved in Europe

In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark


Sputnik V needs to be priced at par with Covishield & Covaxin
News | April 23, 2021

Sputnik V needs to be priced at par with Covishield & Covaxin

Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply


Lonza and Immunitas announce manufacturing agreement
News | April 18, 2021

Lonza and Immunitas announce manufacturing agreement

Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies


IMPCL revenue crosses Rs. 160 crore
News | April 15, 2021

IMPCL revenue crosses Rs. 160 crore

Presently, IMPCL is manufacturing 656 classical Ayurvedic, 332 Unani and 71 proprietary Ayurvedic medicines for the various diseases spectrum


Pharma PLI to increase exports
Policy | April 14, 2021

Pharma PLI to increase exports

Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28


Aurore to merge with Solara in an all-stock transaction
News | April 10, 2021

Aurore to merge with Solara in an all-stock transaction

The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions


Zydus Cadila announces USFDA approval for Ibrutinib capsules
News | April 08, 2021

Zydus Cadila announces USFDA approval for Ibrutinib capsules

Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.


Piramal Enterprises forays into peptide with Hemmo Pharma : ICICI Securities
News | April 05, 2021

Piramal Enterprises forays into peptide with Hemmo Pharma : ICICI Securities

ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E


Reports on GSK Pharmaceuticals by ICICI Securities
News | April 03, 2021

Reports on GSK Pharmaceuticals by ICICI Securities

GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn